Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Study simplifies bladder cancer molecular subtypes

Publish date:: January 2, 2020

Key clinical point: Muscle-invasive bladder cancer can be divided into six molecular classes that may guide prognosis and treatment planning.

Major finding: Neuroendocrine-like muscle-invasive bladder cancer tumors were associated with the poorest outcome (hazard ratio, 2.34; P less than .03).

Study details: A group consensus based on a retrospective meta-analysis involving 1,750 transcriptomic profiles.

Disclosures: The investigators reported relationships with Bayer, Astellas, Genentech, and others.

Citation:

Kamoun A et al. Eur Urol. 2019 Sep 26. doi: 10.1016/j.eururo.2019.09.006.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Genitourinary Cancer

Study shows no link between race and mortality in clear cell RCC,

Four factors may predict better survival with cabozantinib in mRCC,

Focal radiation boost nets better outcomes in prostate cancer,

Fear of recurrence highly prevalent in RCC survivors,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,